CytRx, a biopharmaceutical research and development company specializing in oncology, is currently developing three programs for multiple cancer indications. The company’s lead candidate is aldoxorubicin, a modified version of the widely used chemotherapy agent doxorubicin.
The company’s progress recently got the attention of Seeking Alpha contributor, Equity Options Guru, who considers CYTR a forgotten but “major opportunity” player in the healthcare space.
“With tens of billions of dollars being poured into cancer research each year, the companies involved in this space are attempting to create the next breakthrough therapy that can help alleviate suffering for many patients around the world. One such company, CytRx Corporation (CYTR), appears poised for greatness but it hasn’t participated in the cancer rally over the past few years which begs the question, why not?,” he questions in the article titled “CytRx Corporation Remains an Undiscovered Opportunity in the Caner Space.”
In demonstrating the valuation, opportunity, and advances of comparable players in the oncology market, the article lays out four main reasons for a bullish take on the company:
Hedge fund Baker Brothers’ stake of 1 million shares of CYTR stock
CYTR’s advantages over other biotech platforms
Simple and Effective Mechanism
Minimizing Toxicity
Applicable to Several Forms of Cancer
Intellectual Property Strength
Market potential and favorable clinical performance of aldoxorubicin
Solid cash position with low burn rate
Equity Options Guru sees CYTR as a low-risk option, noting that the company’s diversity in potential treatments dilutes the risk of complete share price collapse in the event that one clinical trial should fail.
“CytRx appears to have the makings of a company poised for a significant run over the next couple of years. The risks appear to be minimal while the potential appears to be enormous particularly if aldoxorubicin works for glioblastoma,” the author writes. “Over the next couple of years, CytRx will be making a series of significant announcements including results from several trials. Investors should strongly consider keeping this company on their radar and perhaps even making an investment.”
To read the Seeking Alpha article in its entirety visit: http://seekingalpha.com/article/1700372
For more information visit www.CytRx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
